Literature DB >> 19463459

Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial.

Lauren J Kim1, Spencer B King, Kenneth Kent, Maria Mori Brooks, Kevin E Kip, J Dawn Abbott, Alice K Jacobs, Charanjit Rihal, Whady A Hueb, Edwin Alderman, Ivan R Pena Sing, Michael J Attubato, Frederick Feit.   

Abstract

OBJECTIVES: We evaluated demographic, clinical, and angiographic factors influencing the selection of coronary artery bypass graft (CABG) surgery versus percutaneous coronary intervention (PCI) in diabetic patients with multivessel coronary artery disease (CAD) in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial.
BACKGROUND: Factors guiding selection of mode of revascularization for patients with diabetes mellitus and multivessel CAD are not clearly defined.
METHODS: In the BARI 2D trial, the selected revascularization strategy, CABG or PCI, was based on physician discretion, declared independent of randomization to either immediate or deferred revascularization if clinically warranted. We analyzed factors favoring selection of CABG versus PCI in 1,593 diabetic patients with multivessel CAD enrolled between 2001 and 2005.
RESULTS: Selection of CABG over PCI was declared in 44% of patients and was driven by angiographic factors including triple vessel disease (odds ratio [OR]: 4.43), left anterior descending stenosis >or=70% (OR: 2.86), proximal left anterior descending stenosis >or=50% (OR: 1.78), total occlusion (OR: 2.35), and multiple class C lesions (OR: 2.06) (all p < 0.005). Nonangiographic predictors of CABG included age >or=65 years (OR: 1.43, p = 0.011) and non-U.S. region (OR: 2.89, p = 0.017). Absence of prior PCI (OR: 0.45, p < 0.001) and the availability of drug-eluting stents conferred a lower probability of choosing CABG (OR: 0.60, p = 0.003).
CONCLUSIONS: The majority of diabetic patients with multivessel disease were selected for PCI rather than CABG. Preference for CABG over PCI was largely based on angiographic features related to the extent, location, and nature of CAD, as well as geographic, demographic, and clinical factors. (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes [BARI 2D]; NCT00006305).

Entities:  

Mesh:

Year:  2009        PMID: 19463459      PMCID: PMC3625397          DOI: 10.1016/j.jcin.2009.01.009

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  23 in total

1.  Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. BARI Investigators.

Authors:  F Feit; M M Brooks; G Sopko; N M Keller; A Rosen; R Krone; P B Berger; R Shemin; M J Attubato; D O Williams; R Frye; K M Detre
Journal:  Circulation       Date:  2000-06-20       Impact factor: 29.690

2.  ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions.

Authors:  S C Smith; J T Dove; A K Jacobs; J W Kennedy; D Kereiakes; M J Kern; R E Kuntz; J J Popma; H V Schaff; D O Williams; R J Gibbons; J P Alpert; K A Eagle; D P Faxon; V Fuster; T J Gardner; G Gregoratos; R O Russell; S C Smith
Journal:  Circulation       Date:  2001-06-19       Impact factor: 29.690

3.  Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group VI: revascularization in diabetic patients.

Authors:  Sidney C Smith; David Faxon; Wayne Cascio; Hartzell Schaff; Timothy Gardner; Alice Jacobs; Steven Nissen; Rick Stouffer
Journal:  Circulation       Date:  2002-05-07       Impact factor: 29.690

4.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

5.  Influence of the Angioplasty Revascularization Investigation National Heart, Lung, and Blood Institute Diabetic Clinical Alert on practice patterns: results from the National Cardiovascular Network Database.

Authors:  Darren K McGuire; Kevin J Anstrom; Eric D Peterson
Journal:  Circulation       Date:  2003-03-31       Impact factor: 29.690

6.  One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  Circulation       Date:  2004-04-12       Impact factor: 29.690

7.  Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Authors: 
Journal:  Am Heart J       Date:  2008-07-31       Impact factor: 4.749

8.  Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis.

Authors:  David R Holmes; Martin B Leon; Jeffrey W Moses; Jeffrey J Popma; Donald Cutlip; Peter J Fitzgerald; Charles Brown; Tim Fischell; Shing Chiu Wong; Mark Midei; David Snead; Richard E Kuntz
Journal:  Circulation       Date:  2004-02-10       Impact factor: 29.690

9.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

Authors:  Rory Collins; Jane Armitage; Sarah Parish; Peter Sleigh; Richard Peto
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

10.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

Authors:  Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

View more
  14 in total

1.  Implications of randomized studies of medical therapy vs revascularization for reducing rising costs of health care.

Authors:  George A Beller
Journal:  J Nucl Cardiol       Date:  2009-06-27       Impact factor: 5.952

2.  Coronary artery bypass in patients with type 2 diabetes: experience from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.

Authors:  Edward Y Sako; Maria Mori Brooks; Regina M Hardison; Hartzel Schaff; Robert L Frye
Journal:  J Thorac Cardiovasc Surg       Date:  2014-01-02       Impact factor: 5.209

Review 3.  SYNTAX Score and Outcomes of Coronary Revascularization in Diabetic Patients.

Authors:  Amartya Kundu; Partha Sardar; Kevin O'Day; Saurav Chatterjee; Theophilus Owan; J Dawn Abbott
Journal:  Curr Cardiol Rep       Date:  2018-03-23       Impact factor: 2.931

Review 4.  Revascularization for Advanced Coronary Artery Disease in Type 2 Diabetic Patients: Choosing Wisely Between PCI and Surgery.

Authors:  Louai Razzouk; Frederick Feit; Michael E Farkouh
Journal:  Curr Cardiol Rep       Date:  2017-05       Impact factor: 2.931

5.  Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.

Authors:  Maria Mori Brooks; Sheng-Chia Chung; Tarek Helmy; William B Hillegass; Jorge Escobedo; Kathryn A Melsop; Elaine M Massaro; Robert D McBane; Pamela Hyde; Mark A Hlatky
Journal:  Circulation       Date:  2010-10-11       Impact factor: 29.690

Review 6.  Chronic coronary artery disease: diagnosis and management.

Authors:  Andrew Cassar; David R Holmes; Charanjit S Rihal; Bernard J Gersh
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

7.  Myocardial perfusion imaging (MPI) is superior to the demonstration of distal collaterals in predicting cardiac events in chronic total occlusion (CTO).

Authors:  Samuel Wright; Meir Lichtenstein; Leeanne Grigg; Dinesh Sivaratnam
Journal:  J Nucl Cardiol       Date:  2013-03-12       Impact factor: 5.952

8.  The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction.

Authors:  Bernard R Chaitman; Regina M Hardison; Dale Adler; Suzanne Gebhart; Mary Grogan; Salvador Ocampo; George Sopko; Jose A Ramires; David Schneider; Robert L Frye
Journal:  Circulation       Date:  2009-11-17       Impact factor: 29.690

9.  Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Authors:  Maria Mori Brooks; Bernard R Chaitman; Richard W Nesto; Regina M Hardison; Frederick Feit; Bernard J Gersh; Ronald J Krone; Edward Y Sako; William J Rogers; Alan J Garber; Spencer B King; Charles J Davidson; Fumiaki Ikeno; Robert L Frye
Journal:  Circulation       Date:  2012-09-24       Impact factor: 29.690

10.  A randomized trial of therapies for type 2 diabetes and coronary artery disease.

Authors:  Robert L Frye; Phyllis August; Maria Mori Brooks; Regina M Hardison; Sheryl F Kelsey; Joan M MacGregor; Trevor J Orchard; Bernard R Chaitman; Saul M Genuth; Suzanne H Goldberg; Mark A Hlatky; Teresa L Z Jones; Mark E Molitch; Richard W Nesto; Edward Y Sako; Burton E Sobel
Journal:  N Engl J Med       Date:  2009-06-07       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.